Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Minocycline Hydrochloride in Glioblastoma: NCT07735819 Clinical Landscape Report 2026
11 September 2026
NCT07735819 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ravulizumab-CWVZ in Myasthenia Gravis: NCT07596784 Clinical Landscape Report 2026
11 September 2026
NCT07596784 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Busulfan in Recurrent Multiple Myeloma: NCT07759102 Clinical Landscape Report 2026
11 September 2026
NCT07759102 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ficerafusp alfa in Squamous cell carcinoma of head and neck metastatic: NCT07807163 Clinical Landscape Report 2026
11 September 2026
NCT07807163 clinical landscape for Squamous cell carcinoma of head and neck metastatic: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Ipilimumab in Melanoma, Cutaneous Malignant: NCT07740941 Clinical Landscape Report 2026
11 September 2026
NCT07740941 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HRS-4729 in Metabolic Dysfunction Associated Steatohepatitis: NCT07660848 Clinical Landscape Report 2026
11 September 2026
NCT07660848 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Iparomlimab/Tuvonralimab in Mesothelioma: NCT07514793 Clinical Landscape Report 2026
11 September 2026
NCT07514793 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PBSS-1113 in Acute Myeloid Leukemia: NCT07761533 Clinical Landscape Report 2026
11 September 2026
NCT07761533 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in Mantle cell lymphoma refractory: NCT07748364 Clinical Landscape Report 2026
11 September 2026
NCT07748364 clinical landscape for Mantle cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oxaliplatin in Locally Advanced Rectal Carcinoma: NCT07811076 Clinical Landscape Report 2026
11 September 2026
NCT07811076 clinical landscape for Locally Advanced Rectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
MWN-109 in Diabetes Mellitus, Type 2: NCT07801326 Clinical Landscape Report 2026
11 September 2026
NCT07801326 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT07768436 Clinical Landscape Report 2026
11 September 2026
NCT07768436 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.